For some, this can be a more comfortable option with less potential for soreness, making it a great choice for ongoing wellness memberships
GLP-1 receptor agonists may offer a new approach that can complement existing topical, systemic and biologic treatment options. Across the trials, clinicians treated participants with one of three GLP-1s 81.5% received semaglutide (Wegovy, Novo Nordisk), 17.4% received liraglutide and 1% received tirzepatide (Zepbound, Eli Lilly) at varying dosages and treatment durations
Treb, R
In general, they appear to be safepartly because rather than adding new substances or chemicals, our bodies already use peptides to communicate
Ill just add that this is all in type 1 diabetes
It is a 43-amino-acid peptide, larger than BPC-157, which makes it slightly more susceptible to structural changes in solution